Signal active
Bio
Vic Hebert joined the company in October 2008 after having been its principal outside counsel at Heller Ehrman LLP since the founding of Burrill & Company. Mr. Hebert is a business lawyer with extensive experience in mergers and acquisitions, corporate finance, corporate governance, fund formation and venture capital.
During his legal career, Mr. Hebert performed services for Heller Ehrman and clients in numerous industries, including biotechnology, healthcare, financial services, aluminum, steel, telecommunications, semiconductor equipment and services, analytical instruments, computer software and hardware, forest products, solid waste disposal, food and beverages.
Mr. Hebert has a long history of serving on the boards of or as an officer of numerous public and private corporations and non-profit organizations. At Heller Ehrman LLP, Mr. Hebert served as Chairman of the Management Committee from 1981-1993 and as Co-Chairman from 1987-1993.
Mr. Hebert is a member of the State Bar of California and a member of the American Bar Association and Bar Association of San Francisco. Mr. Hebert holds undergraduate and law degrees from the University of California, Berkeley.
Location
San Francisco, California, United States, North America
Social
Primary Organization
1994
94
18
27
11-50
Venture Capital, Finance, Biotechnology
Jobs history
0
N/A
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Victor Hebert is the Managing Director, Chief Admisitrative Officer, and Chief Legal Officer at Burrill & Company, based in United States, North America. With a background in Venture Capital, Victor Hebert has a rich history of leadership and innovation. Victor Hebert studied JD unknown @ University of California Berkeley. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
1
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
May 29, 2013 | NewBridge Pharmaceuticals | Series C - NewBridge Pharmaceuticals | Burrill & Company | 48.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.